Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

READY

Financiado

Cerrado

Getting ready to treat human patients with nanobody targeted photodynamic therap...

Getting ready to treat human patients with nanobody targeted photodynamic therapy Unfortunately, current cancer therapies often fail to cure patients, or are associated with severe side effects. Ideally, a therapy should locally eradicate cancer cells without damaging healthy tissue and should induce long term... ver más

30/04/2022

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

150.00K€ | Lider

TRABAJOS CATASTRALES

298.57K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

KILLCANCER Nanobody targeted photodynamic therapy to kill cancer 2M€ Cerrado

SAF2014-54057-R DESARROLLO DE NANOMEDICINAS PARA TERAPIAS ANTITUMORALES E IN... 242K€ Cerrado

NanoPDT Efficient Tumor Targeting and Therapy Using Near Infrared Na... 269K€ Cerrado

CTQ2010-20870-C03-02 NUEVAS ESTRATEGIAS PARA TERAPIA FOTODINAMICA DIRIGIDA. 3. SI... 44K€ Cerrado

POLYMMUNE Off the Shelf Polypeptide based Immunotherapy for Advanced M... 150K€ Cerrado

PATHFINDER Mimicking pathogens an integrated nano medicine approach to... 2M€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2019-12-03
Fecha Fin: 2022-04-30

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Unfortunately, current cancer therapies often fail to cure patients, or are associated with severe side effects. Ideally, a therapy should locally eradicate cancer cells without damaging healthy tissue and should induce long term protection through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach which can do both, through the local light activation of photosensitizers. However, current photosensitizers lack cancer specificity, which limits therapeutic efficacy and prolongs photosensitivity in patients. Recently, Dr. Oliveira has developed an improved version of targeted PDT that uses small antibody fragments, i.e. nanobodies, to target the photosensitizer to cancer cells. Nanobodies distribute homogenously, bind rapidly and specifically to cancer cells, and are quickly eliminated when unbound. Within the ERC StG KILLCANCER project, the team has been focusing on better understanding the mechanism of nanobody-targeted PDT, its potential to induce tumor regression in vivo, and its capacity to trigger the immune system for long term protection. Results indicate this treatment could lead to improved selectivity and reduced side effects, compared to conventional PDT and antibody-targeted PDT. The fundamental objective of this ERC PoC is to ascertain the technical and commercial viability of nanobody-targeted PDT for treatment of head and neck cancer. Within this project, the aims are to: 1. Humanize the lead nanobody, validate the results, and explore GMP production 2. Perform an IP landscape analysis and establish freedom-to-operate (FTO) 3. Execute an extensive market, competitor, and stakeholder analysis, and 4. Develop a detailed business plan based on this information to accurately guide commercialisation. Together, these steps will be essential for nanobody-targeted PDT to be ready for the translation to humans, so that cancer patients and society as a whole can benefit from this promising alternative treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores